Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience has commissioned a third human pilot study to test the oral capsule form of DehydraTECH-processed tirzepatide, a diabetes treatment currently only available as an injection (Zepbound® by Eli Lilly). The study will assess the drug’s absorption and effects on blood sugar levels, with the aim of offering a potentially more tolerable oral medication alternative for patients. Lexaria anticipates a significant breakthrough if the oral delivery of tirzepatide shows measurable bloodstream absorption and improved tolerability.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
